Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (SE:CANTA)
:CANTA
CANTA Stock Chart & Stats
kr4.98
-kr0.02(-1.25%)
At close: 4:00 PM EST
kr4.98
-kr0.02(-1.25%)
Day’s Range― - ―
52-Week Rangekr1.00 - kr5.02
Previous CloseN/A
Volume611.88K
Average Volume (3M)1.42M
Market Cap
€1.24B
Enterprise Valuekr276.13M
Total Cash (Recent Filing)€339.14M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)9.8
Beta0.75
Next Earnings
Feb 20, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.67
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.03Price Target Upside181.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial ReadinessNadunolimab is positioned for a pivotal study with a companion diagnostic in development to support a first-line pancreatic cancer trial, clarifying the regulatory pathway.
Revenue Diversification And Reduced R&D BurdenMilestone payments and royalties from the CAN10 transaction reduce capital needs while preserving upside, and continued preclinical advances broaden long-term value drivers.
Strategic Partnership ValidationAcquisition of the CAN10 program by Otsuka provides external scientific validation and an upfront non-dilutive payment that strengthens development credibility.
Bears Say
Confirmed Clinical Failure In TNBCFinal overall survival data from the TRIFOUR study confirmed lack of efficacy in triple-negative breast cancer, removing potential value for that indication.
Primary Endpoint MissThe Phase 2 TRIFOUR study did not meet its primary response endpoint against chemotherapy, lowering the probability of approval in the breast cancer setting.
Valuation And Sentiment PressureConfirmed program failure in TNBC may maintain negative investor sentiment and justify a valuation write-down for the affected program, pressuring stock performance.
Cantargia AB News
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.00 and its highest was kr5.02 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is €1.24B.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Feb 20, 2026 which is in 39 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Nov 19, 2025. The company reported kr1.07 earnings per share for the quarter, beating the consensus estimate of -kr0.17 by kr1.24.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.19.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of kr1.07 in its last earnings report, beating expectations of -kr0.17. Following the earnings report the stock price went down -7.445%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
CANTA Stock 12 Month Forecast
Average Price Target
kr14.03
▲(181.77% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
―
Guard Therapeutics International AB
―
Immunicum AB
―